...
首页> 外文期刊>Journal of Vascular and Interventional Neurology >Seizure Prophylaxis in the Immediate Post-Hemorrhagic Period in Patients with Aneurysmal Subarachnoid Hemorrhage
【24h】

Seizure Prophylaxis in the Immediate Post-Hemorrhagic Period in Patients with Aneurysmal Subarachnoid Hemorrhage

机译:动脉瘤性蛛网膜下腔出血患者出血后即刻的癫痫预防

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Introduction Seizures are a well-known complication of aneurysmal subarachnoid hemorrhage (aSAH) and occur most commonly in the immediate posthemorrhagic period. Most commonly used antiepileptic drugs (AEDs) for seizure prophylaxis in aSAH include phenytoin and levetiracetam. There is no reliable data available on the safety and efficacy of restricting AED prophylaxis only till the aneurysm is secured. Methods We retrospectively chart reviewed patients admitted to our neurosciences intensive care unit (NICU) with aSAH during the past two years. Seizure incidence was studied in patients treated with phenytoin versus levetiracetam and in patients treated for 3–7 days vs. those where AED was discontinued immediately after aneurysm was secured. Results In 28 patients, AED prophylaxis was discontinued immediately after the aneurysm was secured, and in 21 patients, it was continued for 3–7 days. Of the 28 patients who received AED prophylaxis for less than or equal to two days, phenytoin was used in 20 patients and levetiracetam was used in eight patients. In patients receiving AED prophylaxis for 3–7 days, phenytoin was used in eight cases and levetiracetam was used in 13 cases. None of these patients had seizures reported during hospitalization or at three-month follow-up. Conclusion Stopping the AED prophylaxis immediately after aneurysm coiling is not associated with increased risk of seizures. Seizures at presentation in patients with aSAH are not associated with development of epilepsy at three months. Both phenytoin and levetiracetam are well tolerated in patients with aSAH when limited to the immediate posthemorrhagic period.
机译:简介癫痫发作是动脉瘤性蛛网膜下腔出血(aSAH)的众所周知的并发症,最常见于出血后立即发生的时期。用于预防aSAH中癫痫发作的最常用抗癫痫药(AED)包括苯妥英钠和左乙拉西坦。仅在固定动脉瘤之前,尚无可靠数据可用于限制AED预防的安全性和有效性。方法我们回顾性地回顾了过去两年来被纳入我们的神经科学重症监护病房(NICU)并接受aSAH的患者的图表。在接受苯妥英钠与左乙拉西坦治疗的患者以及治疗3–7天的患者与确诊动脉瘤后立即停用AED的患者中,研究了癫痫发作的发生率。结果在28例患者中,固定了动脉瘤后立即停止了AED预防,在21例患者中,继续进行了3-7天。在接受AED预防少于或等于两天的28例患者中,苯妥英钠用于20例患者,左乙拉西坦用于8例患者。在接受AED预防3-7天的患者中,苯妥英钠8例,左乙拉西坦13例。这些患者在住院期间或三个月的随访中均未发现癫痫发作。结论动脉瘤缠绕后立即停止AED预防与癫痫发作风险增加无关。在aSAH患者中出现癫痫发作与三个月后癫痫的发展无关。仅限于出血后即刻,苯丙氨酸妥拉汀和左乙拉西坦均能很好地耐受aSAH患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号